SCHEMBL4896988

SCHEMBL4896988

N#Cc1c(-c2ccccc2)c2c([nH]c1=O)sc1c(N)ncnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
LIMK1 P53667 5/20 0.45
PDE9A O76083 1/20 0.43
XDH P47989 1/20 0.42
PIM1 P11309 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PRKAG1 P54619 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
CDK5 Q00535 2/20 0.39
DYRK1A Q13627 2/20 0.39
CDC7 O00311 1/20 0.39
CLK1 P49759 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
CDK5R1 Q15078 1/20 0.39
HPGD P15428 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL935581 0.67 ALDH1A1 (0.67) IDO1PDE9AXDHMEN1KMT2A
SCHEMBL5919344 0.65 PRKAG1 (0.59) IDO1PDE9APIM1PRKAG1PRKAA1
SCHEMBL5243274 0.65 LIMK1 (0.52) LIMK1PIM1CDK5DYRK1ACDC7
SCHEMBL5244491 0.64 LIMK1 (0.61) LIMK1PIM1CDK5DYRK1ACDC7
SCHEMBL1176944 0.64 IDO1 (0.59) IDO1XDHMEN1KMT2ACDK5
SCHEMBL12822244 0.62 LIMK1 (1.00) LIMK1PIM1CDK5DYRK1ACDC7
SCHEMBL14872209 0.62 PDE9A (0.60) IDO1PDE9AXDHPIM1MEN1
SCHEMBL5618046 0.61 PDE9A (1.00) IDO1PDE9AMEN1KMT2AHPGD
SCHEMBL4896653 0.61 CDC7 (0.64) LIMK1PIM1CDK5DYRK1ACDC7
SCHEMBL1191061 0.61 PRKAG1 (0.48) PRKAG1PRKAA1PRKAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012131297-A1 PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE BAELL JONATHAN BAYLDON (AU) 2012-10-04 WO disclosed
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses CYWIN CHARLES L 2008-01-10 US disclosed
US-7291733-B2 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
US-20050101601-A1 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101601-A1 Substituted tricyclic heterocycles and their uses LTC4S, NQO1, CBR3 IDO1 614/4885LIMK1 4013/4885PDE9A 1961/4885
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses LTC4S, NQO1, CBR3 IDO1 614/4885LIMK1 4013/4885PDE9A 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.